278 related articles for article (PubMed ID: 24566599)
1. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD
Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599
[TBL] [Abstract][Full Text] [Related]
2. Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials.
Shorr AF; Kollef M; Eckburg PB; Llorens L; Friedland HD
Diagn Microbiol Infect Dis; 2013 Mar; 75(3):298-303. PubMed ID: 23357290
[TBL] [Abstract][Full Text] [Related]
3. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566
[TBL] [Abstract][Full Text] [Related]
4. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
File TM; Wilcox MH; Stein GE
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
[TBL] [Abstract][Full Text] [Related]
5. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Low DE; File TM; Eckburg PB; Talbot GH; David Friedland H; Lee J; Llorens L; Critchley IA; Thye DA;
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii33-44. PubMed ID: 21482568
[TBL] [Abstract][Full Text] [Related]
6. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
Cannavino CR; Nemeth A; Korczowski B; Bradley JS; O'Neal T; Jandourek A; Friedland HD; Kaplan SL
Pediatr Infect Dis J; 2016 Jul; 35(7):752-9. PubMed ID: 27093162
[TBL] [Abstract][Full Text] [Related]
8. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Rank DR; Friedland HD; Laudano JB
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley I; Thye D
Clin Infect Dis; 2010 Dec; 51(12):1395-405. PubMed ID: 21067350
[TBL] [Abstract][Full Text] [Related]
10. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
Taboada M; Melnick D; Iaconis JP; Sun F; Zhong NS; File TM; Llorens L; Friedland HD; Wilson D
J Antimicrob Chemother; 2016 Apr; 71(4):862-70. PubMed ID: 26702925
[TBL] [Abstract][Full Text] [Related]
11. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
[TBL] [Abstract][Full Text] [Related]
12. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
Zhong NS; Sun T; Zhuo C; D'Souza G; Lee SH; Lan NH; Chiang CH; Wilson D; Sun F; Iaconis J; Melnick D
Lancet Infect Dis; 2015 Feb; 15(2):161-71. PubMed ID: 25539586
[TBL] [Abstract][Full Text] [Related]
13. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
DiMondi VP; Drew RH; Chen LF
Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323
[TBL] [Abstract][Full Text] [Related]
14. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
[TBL] [Abstract][Full Text] [Related]
15. A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia.
Blumer JL; Ghonghadze T; Cannavino C; O'Neal T; Jandourek A; Friedland HD; Bradley JS
Pediatr Infect Dis J; 2016 Jul; 35(7):760-6. PubMed ID: 27078119
[TBL] [Abstract][Full Text] [Related]
16. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
Guervil DJ; Kaye KS; Hassoun A; Cole P; Huang XY; Friedland HD
J Chemother; 2016 Jun; 28(3):180-6. PubMed ID: 25817579
[TBL] [Abstract][Full Text] [Related]
17. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
Udeani G; Evans J; Cole P; Friedland HD
Hosp Pract (1995); 2014 Aug; 42(3):109-15. PubMed ID: 25255412
[TBL] [Abstract][Full Text] [Related]
18. Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.
Lodise TP; Anzueto AR; Weber DJ; Shorr AF; Yang M; Smith A; Zhao Q; Huang X; File TM
Antimicrob Agents Chemother; 2015 Feb; 59(2):1119-26. PubMed ID: 25487791
[TBL] [Abstract][Full Text] [Related]
19. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience.
Ramani A; Udeani G; Evans J; Jandourek A; Cole P; Smith A; David Friedland H
J Chemother; 2014 Aug; 26(4):229-34. PubMed ID: 24650326
[TBL] [Abstract][Full Text] [Related]
20. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
Ortiz-Ruiz G; Caballero-Lopez J; Friedland IR; Woods GL; Carides A;
Clin Infect Dis; 2002 Apr; 34(8):1076-83. PubMed ID: 11914996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
